| 标题 |
Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002” |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Baoqing Chen; Zimeng Li; Xingyuan Cheng; Mian Xi 出版日期:2026-08-05 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)